CSL Behring snaps up a closely-held biotech partner and its IL-6 drug — for transplant rejection
Having closely watched and funded a Canadian biotech partner’s IL-6 drug for two and a half years, CSL Behring is snapping it all up. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
